← Back to Search
Efficacy Of Phase 1 Trials In Malignant Pleural Mesothelioma: Description Of A Series Of Patients At A Single Institution.
J. Raphael, G. Le Teuff, A. Hollebecque, C. Massard, R. Bahleda, J. Margery, B. Besse, J. Soria, D. Planchard
Published 2014 · Medicine
Download PDFAnalyze on Scholarcy
BACKGROUND Malignant pleural mesothelioma (MPM) is a locally aggressive disease with a poor prognosis. After failure of first line platinum-based chemotherapy, there is no widely approved salvage regimen. New strategies for treatment are needed and phase 1 trials appear as a rationale alternative. MATERIALS AND METHODS MPM patients were enrolled in 20 different phase 1 trials between March 2005 and January 2012, and their data analyzed retrospectively. The primary endpoint was response rate and secondary endpoints were toxicity profile, overall survival (OS) and progression free survival (PFS). OS and PFS were estimated using Kaplan-Meier and their association with baseline characteristics was investigated through a log-rank test. The drugs described were divided into 5 groups based on their mechanism of action. RESULTS Forty-five patients were analyzed with a median follow up of 20.5 months. The best tumor response was as follows: 4% of patients had a RECIST partial response, 60% had stable disease, 24% had progressive disease and 11% were not evaluable. Grade ≥3 toxicities were observed in 19 (42%) patients. Median OS and PFS were estimated to 6 months (95% CI=[4.2-10.5]) and 2 months (95% CI=[1.3-2.7]), respectively. The cellular motility inhibitors group appeared as the most promising class to be developed in a phase 2 setting. CONCLUSION Including MPM patients in phase I trials beyond first line of treatment can result in modest clinical benefits with an acceptable toxicity profile. Several molecular pathways involved in MPM have been identified and further novel biologic therapies need to be tested.
This paper references
AJCC Cancer Staging Manual
M. B. Amin (2002)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
P. Fong (2009)
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
W. Kelly (2005)
Antiangiogenic therapies for mesothelioma.
J. Dowell (2005)
Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)
A. Nowak (2008)
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
L. Krug (2006)
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
L. Krug (2011)
Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
C. Ferté (2013)
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
D. V. Von Hoff (2009)
Review on clinical trials of targeted treatments in malignant mesothelioma
J. N. Jakobsen (2011)
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
A. Tsao (2007)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
Malignant pleural mesothelioma.
R. Stahel (2009)
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2006)
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
Das maligne Mesotheliom der Pleura
T. Ploenes (2012)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma
A. Sartore-Bianchi (2007)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
J. Van Meerbeeck (1999)
Malignant pleural mesothelioma.
A. Tsao (2009)
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
G. Gordon (2007)
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
Malignant mesothelioma: global incidence and relationship with asbestos.
C. Bianchi (2007)
Predictors of competing mortality in advanced head and neck cancer.
L. Mell (2010)
Systemic treatment of malignant pleural mesothelioma.
F. Grosso (2012)
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2001)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
Emerging therapies for malignant pleural mesothelioma
J. Quispel-Janssen (2012)
Diagnostik und Therapie des malignen Pleuramesothelioms - von der Palliationzur kurativen Intention
P-403 Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107)
T. Jahan (2005)
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients
C. Ferté (2014)
Serum PDGF-AB in Pleural Mesothelioma
R. Filiberti (2005)
Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders.
D. Arber (1998)
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
A. Destro (2006)
Malignant Pleural Mesothelioma: From the Bench to the Bedside
P. Astoul (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Camidge (2012)
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)
This paper is referenced by
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
N. van Zandwijk (2017)
Molecular-Targeted Therapy For Malignant Mesothelioma
Y. Tada (2015)
Acetic acid induces cell death: An in vitro study using normal rat gastric mucosal cell line and rat and human gastric cancer and mesothelioma cell lines
S. Okabe (2014)
Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?
D. Tao (2020)
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
J. Remon (2015)
Multifunctional proteases dipeptidyl peptidase-IV and fibroblast activation protein as possible pathogenetic factors, biomarkers and therapeutic targets in cancer
P. Bušek (2018)
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
D. Papadatos-Pastos (2017)